Linked Life Data

14624341

Source:http://linkedlifedata.com/resource/pubmed/id/14624341

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2003-11-19
pubmed:abstractText
For many years, MVAC chemotherapy has been the standard treatment for patients with advanced bladder cancer. Since only a small proportion of patients with advanced disease may be cured by chemotherapy, the expected toxicity profile has to be balanced against the clinical benefit. It is of importance to select patients who may probably respond to chemotherapy. The treatment-associated toxicity needs to be considered especially in unfit and elderly patients. The introduction of innovative new compounds and combinations for the treatment of advanced bladder cancer has opened new avenues. In particular, the good activity of the synthetic nucleoside analogue gemcitabine has improved chemotherapeutic approaches for older patients. For this group of patients, monotherapy with gemcitabine or paclitaxel as well as combinations with cisplatin, carboplatin, or methotrexate is feasible with acceptable side effects.
pubmed:language
ger
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0340-2592
pubmed:author
pubmed:issnType
Print
pubmed:volume
42
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1445-9
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
[Chemotherapy of bladder cancer. Systemic therapy with reduced toxicity].
pubmed:affiliation
Klinik für Urologie und Kinderurologie, Urologische Universitätsklinik, Ulm. juergen.gschwend@medizin.uni-ulm.de
pubmed:publicationType
Journal Article, Comparative Study, English Abstract